Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor

This is the first report of PARPi rechallenge with bevacizumab as maintenance therapy in this setting. The combination demonstrated promising efficacy, particularly in patients with favorable platinum responsiveness, and warrants further investigation in biomarker-driven studies.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2026-01-29
DOI
https://doi.org/10.1158/1078-0432.ccr-25-2916
Primary Topic
PARP inhibition in cancer therapy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor

Hyun-Woong Cho, DH Jeong, Seungbong Han, Min Chul Choi et al.
Clinical Cancer Research
PARP inhibition in cancer therapy
article

Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor

Hyun-Woong Cho, DH Jeong, Seungbong Han, Min Chul Choi, Jung-Yun Lee, Jungmin Choi, Myong Cheol Lim, Byoung-Gie Kim, E. Pujade-Lauraine, Hae Seo, Jeong-Yeol Park
article en

Abstract

This is the first report of PARPi rechallenge with bevacizumab as maintenance therapy in this setting. The combination demonstrated promising efficacy, particularly in patients with favorable platinum responsiveness, and warrants further investigation in biomarker-driven studies.

Clinical Cancer Research
Seoul National University (KR), Yonsei University (KR), Samsung Medical Center (KR), New Generation University College (ET), Seoul National University Hospital (KR), University of Ulsan (KR), National Cancer Center (US), Inje University Busan Paik Hospital (KR), National Cancer Center (KR), Arcagy Gineco (FR), Korea University (JP)
Good health and well-being
Openalex Percentile: Top 74%
PARP inhibition in cancer therapy
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor — Hyun-Woong Cho, DH Jeong, et al. · Clinical Cancer Research (2026) | TGRS Research Map | TGRS